{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-023988","form_type":"8-K","ticker":"RPRX","cik":"0001802768","company_name":"Royalty Pharma plc","filed_at":"2025-02-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.931631+00:00","generated_at":"2026-05-26T23:28:50.108235+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Royalty Pharma Q4 2024: Royalty Receipts +12% to $729M; 2025 guidance $2.9B–$3.05B","bullets":["Portfolio Receipts $742M in Q4 (+1% YoY); FY 2024 $2,801M (-8% due to $525M Biohaven milestones in 2023).","Net cash from operations $743M in Q4, $2,769M for FY. Adjusted EBITDA $669M (Q4), $2,565M (FY).","2025 Portfolio Receipts guidance $2,900M–$3,050M (+4–9% growth), excluding future transactions.","Capital deployed $2.8B in 2024; new $3B share repurchase program authorized in Jan 2025, $2B planned in 2025.","Acquisition of external manager RP Management for ~$1.1B in equity/cash/debt; expected Q2 2025 close."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-023988","json":"https://secwatch.observer/filing/0001193125-25-023988.json","markdown":"https://secwatch.observer/filing/0001193125-25-023988.md","text":"https://secwatch.observer/filing/0001193125-25-023988.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802768/000119312525023988/0001193125-25-023988-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802768/000119312525023988/d929959d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T23:28:50.108235+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}